Cygnus Technologies

Articles

Predicting Retroviral Particle Clearance with MockV® Retrovirus-like Particles 

AAE-MS™ as an Orthogonal Method in Host Cell Protein Analytics

Leads strategic technical marketing and business development at Cygnus Technologies.

HCP ELISA and HCP Antibody Coverage Analysis Methods

David Cetlin is Senior Director of R&D at Cygnus Technologies. He can be contacted at 

Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, viral vectors, and plasma derivates.